CLAIMS

What is claimed is:

1. An aporphine compound having the following structure I:



I

wherein R_1, R_2, R_6 and R_7 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr, and O^iPr; R_3 and R_5 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; R_4 is selected from allyl and C_nH_{2n+1}, $n \geq 0$; and R_8 is selected from H, OH and OMe.

2. An aporphine compound having the following structure II:



II

wherein R_1 and R_3 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; R_2 is selected from allyl and C_nH_{2n+1}, $n \geq 0$; R_7 is selected from H, OH and OMe; R_4 and R_5 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; and R_6 is selected from H, OH, O-acyl and OMe.

3. An aporphine compound having the following structure III:



III

wherein R_1 and R_2 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3 and R_5 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; R_4 is selected from allyl and C_nH_{2n+1}, $n \geq 0$; and R_6 is selected from H, OH, O-acyl and OMe.

4. An aporphine compound having the following structure IV:



IV

wherein R_1, R_2, R_5 and R_6 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3 and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; and R_7 is selected from H, OH, O-acyl and OMe.

5. An aporphine compound having the following structure V:



V

wherein R_1 and R_2 are each selected from H, acyl, Me, Et, O^nPr and O^iPr; and R_3 and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN.

6. An oxoaporphine compound having the following structure VI:



VI

wherein R_1 and R_2 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NO_2 and CN; R_3 and R_4 are selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; and R_5 is selected from H, OH, O-acyl and OMe.

7. An oxoaporphine compound having the following structure VII:



VII

wherein R_1, R_2, R_5 and R_6 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3 and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NO_2 and CN; and R_7 is selected from H, OH, O-acyl and OMe.

8. An oxoaporphine compound having the following structure VIII:



VIII

wherein R_1 and R_2 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3, and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NO_2 and CN; and R_5 is selected from H, OH, O-acyl and OMe.

9. The aporphine compound of claim 1, wherein the aporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

10. The aporphine compound of claim 2, wherein the aporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

11. The aporphine compound of claim 3, wherein the aporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

12. The aporphine compound of claim 4, wherein the aporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

13. The aporphine compound of claim 5, wherein the aporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

14. The oxoaporphine compound of claim 6, wherein the oxoaporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the

pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

15. The oxoaporphine compound of claim 7, wherein the oxoaporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.

16. The oxoaporphine compound of claim 8, wherein the oxoaporphine compound is in a pharmaceutical composition for preventing or treating an ischemic disease, wherein the pharmaceutical composition comprises an effective amount of the aporphine compound and a pharmaceutically acceptable carrier or excipient.